Soroka Medical Center

BACKGROUND: Trials comparing the effectiveness and safety of weight-loss diets are frequently limited by short follow-up times and high dropout rates. METHODS: In this 2-year trial, we randomly assigned 322 moderately obese subjects (mean age, 52 years; mean body-mass index [the weight in kilograms divided by the square of the height in meters], 31; male sex, 86%) to one of three diets: low-fat, restricted-calorie; Mediterranean, restricted-calorie; or low-carbohydrate, non-restricted-calorie. RESULTS: The rate of adherence to a study diet was 95.4% at 1 year and 84.6% at 2 years. The Mediterranean-diet group consumed the largest amounts of dietary fiber and had the highest ratio of monounsaturated to saturated fat (P<0.05 for all comparisons among treatment groups). The low-carbohydrate group consumed the smallest amount of carbohydrates and the largest amounts of fat, protein, and cholesterol and had the highest percentage of participants with detectable urinary ketones (P<0.05 for all comparisons among treatment groups). The mean weight loss was 2.9 kg for the low-fat group, 4.4 kg for the Mediterranean-diet group, and 4.7 kg for the low-carbohydrate group (P<0.001 for the interaction between diet group and time); among the 272 participants who completed the intervention, the mean weight losses were 3.3 kg, 4.6 kg, and 5.5 kg, respectively. The relative reduction in the ratio of total cholesterol to high-density lipoprotein cholesterol was 20% in the low-carbohydrate group and 12% in the low-fat group (P=0.01). Among the 36 subjects with diabetes, changes in fasting plasma glucose and insulin levels were more favorable among those assigned to the Mediterranean diet than among those assigned to the low-fat diet (P<0.001 for the interaction among diabetes and Mediterranean diet and time with respect to fasting glucose levels). CONCLUSIONS: Mediterranean and low-carbohydrate diets may be effective alternatives to low-fat diets. The more favorable effects on lipids (with the low-carbohydrate diet) and on glycemic control (with the Mediterranean diet) suggest that personal preferences and metabolic considerations might inform individualized tailoring of dietary interventions. (ClinicalTrials.gov number, NCT00160108.)

PURPOSE: In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab significantly improved progression-free survival and overall survival (OS) compared with platinum-based chemotherapy in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) with a programmed death ligand 1 tumor proportion score of 50% or greater and without EGFR/ALK aberrations. We report an updated OS and tolerability analysis, including analyses adjusting for potential bias introduced by crossover from chemotherapy to pembrolizumab. PATIENTS AND METHODS: Patients were randomly assigned to pembrolizumab 200 mg every 3 weeks (for up to 2 years) or investigator's choice of platinum-based chemotherapy (four to six cycles). Patients assigned to chemotherapy could cross over to pembrolizumab upon meeting eligibility criteria. The primary end point was progression-free survival; OS was an important key secondary end point. Crossover adjustment analysis was done using the following three methods: simplified two-stage method, rank-preserving structural failure time, and inverse probability of censoring weighting. RESULTS: Three hundred five patients were randomly assigned (pembrolizumab, n = 154; chemotherapy, n = 151). At data cutoff (July 10, 2017; median follow-up, 25.2 months), 73 patients in the pembrolizumab arm and 96 in the chemotherapy arm had died. Median OS was 30.0 months (95% CI, 18.3 months to not reached) with pembrolizumab and 14.2 months (95% CI, 9.8 to 19.0 months) with chemotherapy (hazard ratio, 0.63; 95% CI, 0.47 to 0.86). Eighty-two patients assigned to chemotherapy crossed over on study to receive pembrolizumab. When adjusted for crossover using the two-stage method, the hazard ratio for OS for pembrolizumab versus chemotherapy was 0.49 (95% CI, 0.34 to 0.69); results using rank-preserving structural failure time and inverse probability of censoring weighting were similar. Treatment-related grade 3 to 5 adverse events were less frequent with pembrolizumab compared with chemotherapy (31.2% v 53.3%, respectively). CONCLUSION: With prolonged follow-up, first-line pembrolizumab monotherapy continues to demonstrate an OS benefit over chemotherapy in patients with previously untreated, advanced NSCLC without EGFR/ALK aberrations, despite crossover from the control arm to pembrolizumab as subsequent therapy.

The implicit paradigm that has governed the study and clinical management of preterm labour is that term and preterm parturition are the same processes, except for the gestational age at which they occur. Indeed, both share a common pathway composed of uterine contractility, cervical dilatation and activation of the membranes/decidua. This review explores the concept that while term labour results from physiological activation of the components of the common pathway, preterm labour arises from pathological signalling and activation of one or more components of the common pathway of parturition. The term "great obstetrical syndromes" has been coined to reframe the concept of obstetrical disease. Such syndromes are characterised by: (1) multiple aetiology; (2) long preclinical stage; (3) frequent fetal involvement; (4) clinical manifestations that are often adaptive in nature; and (5) gene-environment interactions that may predispose to the syndromes. This article reviews the evidence indicating that the pathological processes implicated in the preterm parturition syndrome include: (1) intrauterine infection/inflammation; (2) uterine ischaemia; (3) uterine overdistension; (4) abnormal allograft reaction; (5) allergy; (6) cervical insufficiency; and (7) hormonal disorders (progesterone related and corticotrophin-releasing factor related). The implications of this conceptual framework for the prevention, diagnosis, and treatment of preterm labour are discussed.

PURPOSE: In KEYNOTE-189, first-line pembrolizumab plus pemetrexed-platinum significantly improved overall survival (OS) and progression-free survival (PFS) compared with placebo plus pemetrexed-platinum in patients with metastatic nonsquamous non‒small-cell lung cancer (NSCLC), irrespective of tumor programmed death-ligand 1 (PD-L1) expression. We report an updated analysis from KEYNOTE-189 (ClinicalTrials.gov: NCT02578680). METHODS: Patients were randomly assigned (2:1) to receive pemetrexed and platinum plus pembrolizumab (n = 410) or placebo (n = 206) every 3 weeks for 4 cycles, then pemetrexed maintenance plus pembrolizumab or placebo for up to a total of 35 cycles. Eligible patients with disease progression in the placebo-combination group could cross over to pembrolizumab monotherapy. Response was assessed per RECIST (version 1.1) by central review. No alpha was assigned to this updated analysis. RESULTS: As of September 21, 2018 (median follow-up, 23.1 months), the updated median (95% CI) OS was 22.0 (19.5 to 25.2) months in the pembrolizumab-combination group versus 10.7 (8.7 to 13.6) months in the placebo-combination group (hazard ratio [HR], 0.56; 95% CI, 0.45 to 0.70]). Median (95% CI) PFS was 9.0 (8.1 to 9.9) months and 4.9 (4.7 to 5.5) months, respectively (HR, 0.48; 95% CI, 0.40 to 0.58). Median (95% CI) time from randomization to objective tumor progression on next-line treatment or death from any cause, whichever occurred first (progression-free-survival-2; PFS-2) was 17.0 (15.1 to 19.4) months and 9.0 (7.6 to 10.4) months, respectively (HR, 0.49; 95% CI, 0.40 to 0.59). OS and PFS benefits with pembrolizumab were observed regardless of PD-L1 expression or presence of liver/brain metastases. Incidence of grade 3-5 adverse events was similar in the pembrolizumab-combination (71.9%) and placebo-combination (66.8%) groups. CONCLUSION: First-line pembrolizumab plus pemetrexed-platinum continued to demonstrate substantially improved OS and PFS in metastatic nonsquamous NSCLC, regardless of PD-L1 expression or liver/brain metastases, with manageable safety and tolerability.

BACKGROUND: fusion-positive NSCLC, the efficacy and safety of selective RET inhibition are unknown. METHODS: fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated separately in a phase 1-2 trial of selpercatinib. The primary end point was an objective response (a complete or partial response) as determined by an independent review committee. Secondary end points included the duration of response, progression-free survival, and safety. RESULTS: fusion-positive NSCLC who had previously received at least platinum-based chemotherapy, the percentage with an objective response was 64% (95% confidence interval [CI], 54 to 73). The median duration of response was 17.5 months (95% CI, 12.0 to could not be evaluated), and 63% of the responses were ongoing at a median follow-up of 12.1 months. Among 39 previously untreated patients, the percentage with an objective response was 85% (95% CI, 70 to 94), and 90% of the responses were ongoing at 6 months. Among 11 patients with measurable central nervous system metastasis at enrollment, the percentage with an objective intracranial response was 91% (95% CI, 59 to 100). The most common adverse events of grade 3 or higher were hypertension (in 14% of the patients), an increased alanine aminotransferase level (in 12%), an increased aspartate aminotransferase level (in 10%), hyponatremia (in 6%), and lymphopenia (in 6%). A total of 12 of 531 patients (2%) discontinued selpercatinib because of a drug-related adverse event. CONCLUSIONS: fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated. (Funded by Loxo Oncology and others; LIBRETTO-001 ClinicalTrials.gov number, NCT03157128.).

Yale University School of Medicine, New Haven, Connecticut, Soroka University Center and Faculty of Health Sciences, Beer-Sheva, Israel

BACKGROUND: Polyarteritis nodosa is a systemic necrotizing vasculitis with a pathogenesis that is poorly understood. We identified six families with multiple cases of systemic and cutaneous polyarteritis nodosa, consistent with autosomal recessive inheritance. In most cases, onset of the disease occurred during childhood. METHODS: We carried out exome sequencing in persons from multiply affected families of Georgian Jewish or German ancestry. We performed targeted sequencing in additional family members and in unrelated affected persons, 3 of Georgian Jewish ancestry and 14 of Turkish ancestry. Mutations were assessed by testing their effect on enzymatic activity in serum specimens from patients, analysis of protein structure, expression in mammalian cells, and biophysical analysis of purified protein. RESULTS: In all the families, vasculitis was caused by recessive mutations in CECR1, the gene encoding adenosine deaminase 2 (ADA2). All the Georgian Jewish patients were homozygous for a mutation encoding a Gly47Arg substitution, the German patients were compound heterozygous for Arg169Gln and Pro251Leu mutations, and one Turkish patient was compound heterozygous for Gly47Val and Trp264Ser mutations. In the endogamous Georgian Jewish population, the Gly47Arg carrier frequency was 0.102, which is consistent with the high prevalence of disease. The other mutations either were found in only one family member or patient or were extremely rare. ADA2 activity was significantly reduced in serum specimens from patients. Expression in human embryonic kidney 293T cells revealed low amounts of mutant secreted protein. CONCLUSIONS: Recessive loss-of-function mutations of ADA2, a growth factor that is the major extracellular adenosine deaminase, can cause polyarteritis nodosa vasculopathy with highly varied clinical expression. (Funded by the Shaare Zedek Medical Center and others.).

BACKGROUND: Although radiological pneumonia is used as an outcome measure in epidemiological studies, there is considerable variability in the interpretation of chest radiographs. A standardized method for identifying radiological pneumonia would facilitate comparison of the results of vaccine trials and epidemiological studies of pneumonia. METHODS: A WHO working group developed definitions for radiological pneumonia. Inter-observer variability in categorizing a set of 222 chest radiographic images was measured by comparing the readings made by 20 radiologists and clinicians with a reference reading. Intra-observer variability was measured by comparing the initial readings of a randomly chosen subset of 100 radiographs with repeat readings made 8-30 days later. FINDINGS: Of the 222 images, 208 were considered interpretable. The reference reading categorized 43% of these images as showing alveolar consolidation or pleural effusion (primary end-point pneumonia); the proportion thus categorized by each of the 20 readers ranged from 8% to 61%. Using the reference reading as the gold standard, 14 of the 20 readers had sensitivity and specificity of > 0.70 in identifying primary end-point pneumonia; 13 out of 20 readers had a kappa index of > 0.6 compared with the reference reading. For the 92 radiographs deemed to be interpretable among the 100 images used for intra-observer variability, 19 out of 20 readers had a kappa index of > 0.6. CONCLUSION: Using standardized definitions and training, it is possible to achieve agreement in identifying radiological pneumonia, thus facilitating the comparison of results of epidemiological studies that use radiological pneumonia as an outcome.

Recurrent implantation failure (RIF) refers to cases in which women have had three failed in vitro fertilization (IVF) attempts with good quality embryos. The definition should also take advanced maternal age and embryo stage into consideration. The failure of embryo implantation can be a consequence of uterine, male, or embryo factors, or the specific type of IVF protocol. These cases should be investigated to determine the most likely etiologies of the condition, as this is a complex problem with several variables. There are multiple risk factors for recurrent implantation failure including advanced maternal age, smoking status of both parents, elevated body mass index, and stress levels. Immunological factors such as cytokine levels and presence of specific autoantibodies should be examined, as well as any infectious organisms in the uterus leading to chronic endometritis. Uterine pathologies such as polyps and myomas as well as congenital anatomical anomalies should be ruled out. Sperm analysis, pre-implantation genetic screening and endometrial receptivity should be considered and evaluated, and IVF protocols should be tailored to specific patients or patient populations. Treatment approaches should be directed toward individual patient cases. In addition, we suggest considering a new initial step in approach to patients with RIF, individualized planned activities to activate the brain's reward system in attempt to improve immunological balance in the body.

The accurate diagnosis of pneumococcal disease has frequently been hampered not only by the difficulties in obtaining isolates of the organism from patient specimens but also by the misidentification of pneumococcus-like viridans group streptococci (P-LVS) as Streptococcus pneumoniae. This is especially critical when the specimen comes from the respiratory tract. In this study, three novel real-time PCR assays designed for the detection of specific sequence regions of the lytA, ply, and psaA genes were developed (lytA-CDC, ply-CDC, and psaA, respectively). These assays showed high sensitivity (<10 copies for lytA-CDC and ply-CDC and an approximately twofold less sensitivity for psaA). Two additional real-time PCR assays for lytA and ply described previously for pneumococcal DNA detection were also evaluated. A panel of isolates consisting of 67 S. pneumoniae isolates (44 different serotypes and 3 nonencapsulated S. pneumoniae isolates from conjunctivitis outbreaks) and 104 nonpneumococcal isolates was used. The 67 S. pneumoniae isolates were reactive in all five assays. The new real-time detection assays targeting the lytA and psaA genes were the most specific for the detection of isolates confirmed to be S. pneumoniae, with lytA-CDC showing the greatest specificity. Both ply PCRs were positive for all isolates of S. pseudopneumoniae, along with 13 other isolates of other P-LVS isolates confirmed to be non-S. pneumoniae by DNA-DNA reassociation. Thus, the use of the ply gene for the detection of pneumococci can lead to false-positive reactions in the presence of P-LVS. The five assays were applied to 15 culture-positive cerebrospinal fluid specimens with 100% sensitivity; and serum and ear fluid specimens were also evaluated. Both the lytA-CDC and psaA assays, particularly the lytA-CDC assay, have improved specificities compared with those of currently available assays and should therefore be considered the assays of choice for the detection of pneumococcal DNA, particularly when upper respiratory P-LVS might be present in the clinical specimen.

CONTEXT: Macrophage infiltration into adipose tissue has been demonstrated to accompany obesity, with a potential preferential infiltration into intraabdominal vs. sc fat. OBJECTIVE: Our objective was to determine whether this occurs across different populations with a range of body mass indexes and to assess the relationship with regional adiposity and comorbidity of obesity. SETTING AND PATIENTS: In two independent cohorts, we used paired omental (OM) and sc fat biopsies from lean controls or predominantly sc or intraabdominally obese persons with minimal comorbidity (n = 60, cohort 1), or from severely obese women with a significant rate of comorbidity (n = 29, cohort 2). RESULTS: Elevated macrophage infiltration into OM vs. sc fat was observable in lean subjects and exaggerated by obesity, particularly if predominantly intraabdominal. This was paralleled by increased monocyte chemoattractant protein-1 (MCP1) and colony-stimulating factor-1 (CSF1) mRNA levels. Level of CSF1 and MCP1 mRNA correlated with the number of OM macrophages (r = 0.521, P < 0.0001 and r = 0.258, P < 0.051, respectively). In severely obese women (mean body mass index = 43.0 +/- 1.1 kg/m(2)), higher protein expression of both MCP1 and CSF1 was detected in OM vs. sc fat. Number of OM macrophages, but not of sc macrophages, correlated with waist circumference (r = 0.636, P = 0.001 vs. r = 0.170, P = 0.427) and with the number of metabolic syndrome parameters (r = 0.385, P = 0.065 vs. r = -0.158, P = 0.472, respectively). Preferential macrophage infiltration into OM fat was mainly observed in a subgroup in whom obesity was associated with impaired glucose homeostasis. CONCLUSIONS: Preferential macrophage infiltration into OM fat is a general phenomenon exaggerated by central obesity, potentially linking central adiposity with increased risk of diabetes and coronary heart disease.

OBJECTIVE: To investigate the effect of 2 different species of probiotics in preventing infections in infants attending child care centers. METHODS: A double-blind, placebo-controlled, randomized trial was conducted from December 1, 2000, to September 30, 2002, at 14 child care centers in the Beer-Sheva area of Israel in healthy term infants 4 to 10 months old. Infants were assigned randomly to formula supplemented with Bifidobacterium lactis (BB-12), Lactobacillus reuteri (American Type Culture Collection 55730), or no probiotics. Duration of feeding, including follow-up, for each participant was 12 weeks. All infants were fed only the assigned formula and were not breastfed due to parental decision before recruitment to the study. Probiotic or prebiotic food products or supplements were not allowed. Main outcome measures were number of days and number of episodes with fever (>38 degrees C) and number of days and number of episodes with diarrhea or respiratory illness. RESULTS: Participants (n = 201) were similar regarding gestational age, birth weight, gender, and previous breastfeeding. The controls (n = 60), compared with those fed B lactis (n = 73) or L reuteri (n = 68), had significantly more febrile episodes (mean [95% confidence interval]: 0.41 [0.28-0.54] vs 0.27 [0.17-0.37] vs 0.11 [0.04-0.18], respectively). The controls also had more diarrhea episodes (0.31 [0.22-0.40] vs 0.13 [0.05-0.21] vs 0.02 [0.01-0.05], respectively) and episodes of longer duration (0.59 [0.34-0.84] vs 0.37 [0.08-0.66] vs 0.15 [0.12-0.18] days, respectively). The L reuteri group, compared with BB-12 or controls, had a significant decrease of number of days with fever, clinic visits, child care absences, and antibiotic prescriptions. Rate and duration of respiratory illnesses did not differ significantly between groups. CONCLUSIONS: Child care infants fed a formula supplemented with L reuteri or B lactis had fewer and shorter episodes of diarrhea, with no effect on respiratory illnesses. These effects were more prominent with L reuteri, which was also the only supplement to improve additional morbidity parameters.

Introduction: Intravenous(IV) immunoglobulin(Ig) treatment is known to alleviate behavioral deficits in the experimentally induced model of sepsis. To delineate the mechanisms by which IVIg treatment prevents neuronal dysfunction, an array of immunological and apoptosis markers was investigated. Methods: Sepsis was induced by cecal ligation perforation(CLP) in rats. The animals were divided into five groups; sham, control, CLP + saline, CLP + immunoglobulin G IgG(250 mg/kg,iv), and CLP + immunoglobulins enriched with immunoglobulin M-IgGAM(250 mg/kg,iv). Blood and brain samples were taken in two sets of experiments after CLP to see the early(24 hrs) and late(10 days) effects of treatment. Total complement activity, complement 3(C3) and soluble complement C5b-9 levels were measured in sera of rats using ELISA-based methods. Cerebral complement content was analyzed by Western Blot. Immune cell infiltration and gliosis were examined by immunohistochemistry using cluster of differentiation 3, CD4, CD8, CD11b, CD19 and glial fibrillary acidic protein antibodies. Apoptotic neuronal death was investigated by TUNEL staining and Western Blot-based semi-quantitative evaluation of brain homogenates by bax and bcl-2 antibodies. Results: IV IgG and IgGAM administration significantly reduced systemic complement activity but increased serum C3 and soluble C5b-9 levels. Likewise, Western Blot data showed slightly increased C5b-9 expression and significantly reduced C1q expression in brain samples of IgGAM-treated but not IgG-treated septic rats especially in the first day of administration. No cerebral cellular infiltrates were observed in treated and non-treated septic rats. By contrast, IV IgG and IgGAM treatment induced considerable amelioration in glial cell proliferation which was increased in non-treated rats. IgG and IgGAM treated rats exhibited significantly reduced numbers of apoptotic neurons and cerebral expression levels of bax and bcl-2 as compared to nontreated rats. Conclusions: We suggest that IV IgG and IgGAM administration ameliorates neuronal dysfunction and behavioral deficits by reducing apoptotic cell death and glial cell proliferation. IgGAM treatment might be suppressing classical complement pathway by reducing C1q expression.

The antiproliferative properties of lycopene, the major tomato carotenoid, were compared with those of alpha- and beta-carotene. Lycopene, delivered in cell culture medium from stock solutions in tetrahydrofuran, strongly inhibited proliferation of endometrial (Ishikawa), mammary (MCF-7), and lung (NCI-H226) human cancer cells with half-maximal inhibitory concentration of 1-2 microM; alpha- and beta-carotene were far less effective inhibitors. For example, in Ishikawa cells, a 4-fold higher concentration of alpha-carotene or a 10-fold higher concentration of beta-carotene was needed for the same order of growth suppression. The inhibitory effect of lycopene was detected after 24 hours of incubation, and it was maintained for at least three days. In contrast to cancer cells, human fibroblasts were less sensitive to lycopene, and the cells gradually escaped growth inhibition over time. In addition to its inhibitory effect on basal endometrial cancer cell proliferation, lycopene also suppressed insulin-like growth factor-I-stimulated growth. Insulin-like growth factors are major autocrine/paracrine regulators of mammary and endometrial cancer cell growth. Therefore, lycopene interference in this major autocrine/paracrine system may open new avenues for research on the role of lycopene in the regulation of endometrial cancer and other tumors.

BACKGROUND: Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene containing a premature termination signal cause a deficiency or absence of functional chloride-channel activity. Aminoglycoside antibiotics can suppress premature termination codons, thus permitting translation to continue to the normal end of the transcript. We assessed whether topical administration of gentamicin to the nasal epithelium of patients with cystic fibrosis could result in the expression of functional CFTR channels. METHODS: In a double-blind, placebo-controlled, crossover trial, patients with stop mutations in CFTR or patients homozygous for the DeltaF508 mutation received two drops containing gentamicin (0.3 percent, or 3 mg per milliliter) or placebo in each nostril three times daily for two consecutive periods of 14 days. Nasal potential difference was measured at base line and after each treatment period. Nasal epithelial cells were obtained before and after gentamicin treatment from patients carrying stop mutations, and the C-terminal of surface CFTR was stained. RESULTS: Gentamicin treatment caused a significant reduction in basal potential difference in the 19 patients carrying stop mutations (from -45+/-8 to -34+/-11 mV, P=0.005) and a significant response to chloride-free isoproterenol solution (from 0+/-3.6 to -5+/-2.7 mV, P<0.001). This effect of gentamicin on nasal potential difference occurred both in patients who were homozygous for stop mutations and in those who were heterozygous, but not in patients who were homozygous for DeltaF508. After gentamicin treatment, a significant increase in peripheral and surface staining for CFTR was observed in the nasal epithelial cells of patients carrying stop mutations. CONCLUSIONS: In patients with cystic fibrosis who have premature stop codons, gentamicin can cause translational "read through," resulting in the expression of full-length CFTR protein at the apical cell membrane, and thus can correct the typical electrophysiological abnormalities caused by CFTR dysfunction.

Cardiogenic shock (CS) is a complex multifactorial clinical syndrome with extremely high mortality, developing as a continuum, and progressing from the initial insult (underlying cause) to the subsequent occurrence of organ failure and death. There is a large spectrum of CS presentations resulting from the interaction between an acute cardiac insult and a patient's underlying cardiac and overall medical condition. Phenotyping patients with CS may have clinical impact on management because classification would support initiation of appropriate therapies. CS management should consider appropriate organization of the health care services, and therapies must be given to the appropriately selected patients, in a timely manner, whilst avoiding iatrogenic harm. Although several consensus-driven algorithms have been proposed, CS management remains challenging and substantial investments in research and development have not yielded proof of efficacy and safety for most of the therapies tested, and outcome in this condition remains poor. Future studies should consider the identification of the new pathophysiological targets, and high-quality translational research should facilitate incorporation of more targeted interventions in clinical research protocols, aimed to improve individual patient outcomes. Designing outcome clinical trials in CS remains particularly challenging in this critical and very costly scenario in cardiology, but information from these trials is imperiously needed to better inform the guidelines and clinical practice. The goal of this review is to summarize the current knowledge concerning the definition, epidemiology, underlying causes, pathophysiology and management of CS based on important lessons from clinical trials and registries, with a focus on improving in-hospital management.

Chronic inflammation of adipose tissue in obesity is by now an established phenomenon, but the initiating event(s) of the inflammatory cascade are still unknown. We hypothesized that neutrophil infiltration into adipose tissue may precede macrophage infiltration as in classical immune responses. Here we demonstrate that early (3 and 7 days) after initiating high-fat feeding of C57BL/6J mice, neutrophils transiently infiltrate the parenchyma of intra-abdominal adipose tissue. Mean periepdidymal fat myeloperoxidase expression (representing neutrophils) and and 7 neutrophils and by in neutrophils of in by the in of of the of by neutrophils of of in of that the is by neutrophil and Chronic inflammation of adipose tissue in obesity is by now an established phenomenon, but the initiating event(s) of the inflammatory cascade are still unknown. We hypothesized that neutrophil infiltration into adipose tissue may precede macrophage infiltration as in classical immune responses. Here we demonstrate that early (3 and 7 days) after initiating high-fat feeding of C57BL/6J mice, neutrophils transiently infiltrate the parenchyma of intra-abdominal adipose tissue. Mean periepdidymal fat myeloperoxidase expression (representing neutrophils) and and 7 neutrophils and by in neutrophils of in by the in of of the of by neutrophils of of in of that the is by neutrophil and is as by inflammation inflammatory in adipose is by of inflammatory and and by an of of in adipose tissue. of in adipose and in and and in fat the tissue in in as an and as of inflammatory of the of adipose tissue in the are of as and and adipose tissue in obesity by of are of is macrophage in adipose inflammation in fat in the of now that infiltration of immune in the of that infiltration into adipose tissue in mice, and the of inflammatory and of high-fat macrophage infiltration into adipose and in the of macrophage infiltration into the fat in the and of infiltration of in adipose tissue is in infiltration into fat of and the of the in in and the of inflammatory and inflammatory of and adipose tissue may by immune and may the of obesity of adipose tissue infiltration by in the high-fat of macrophage infiltration of obesity is macrophage in adipose adipose tissue and obesity and inflammatory inflammatory infiltration of by infiltrate is by infiltration of the tissue by neutrophils and may the that in an established of adipose tissue may by immune of the and the that adipose tissue that neutrophils we hypothesized that neutrophil infiltration of adipose tissue may precede the macrophage we the that neutrophils transiently infiltrate adipose tissue as early as after initiating high-fat in We in that neutrophil and and and in the of neutrophils myeloperoxidase and and by and and the the of the and of C57BL/6J of high-fat as adipose tissue and obesity and and by and periepdidymal and fat in the and in and in an of 7 tissue and and into in as we of and in and the of by of by and of in of and by and by after of and of of and and the in neutrophils of and in neutrophils the and the the in of and in the by of the the in the as the of by neutrophils as the of by the as of of the of neutrophils the and in and as of by of of and as the expression of in neutrophils in in the the and by expression of in and the the and by and fat in and of and the the and adipose fat neutrophils by and of in and the the and the neutrophils in in and the of the and as of and in and in the of the as of the of in of and in of in the neutrophils and the in of the and and in of the of and the in in and the of the and the and by neutrophils as of in the of and by and into and the by the in in and of by in of the and fat in and by in of macrophage and in adipose tissue of and and in of in and of by in of by the the and in an of macrophage by the of are as of by of the neutrophils infiltrate adipose tissue macrophage we C57BL/6J mice, obesity high-fat high-fat an of in as early as after of high-fat feeding and high-fat mice, in of in adipose tissue the of adipose tissue we of adipose tissue the the neutrophil adipose tissue expression and and and and of adipose tissue expression of in is in Mean periepdidymal fat expression and and 7 and in expression in in expression in adipose tissue and high-fat and and neutrophils that that of adipose tissue the the of neutrophils the parenchyma of the adipose tissue in neutrophils by in adipose tissue neutrophils in fat of high-fat and 7 high-fat but established adipose tissue by as by macrophage and in adipose tissue of and and 7 and and the of expression that of in intra-abdominal fat of tissue demonstrate that neutrophils transiently infiltrate intra-abdominal adipose tissue early in the of by the infiltration of adipose tissue by infiltration of adipose tissue in of neutrophils by in fat and in high-fat (3 of high-fat are in the are of the after and 7 of high-fat feeding expression is in of fat high-fat high-fat neutrophils of as in the of we an in the of neutrophils the We the in neutrophils the of the in We by neutrophils of of the neutrophils the and of by the of neutrophils the the in the of neutrophils and in the of of the of in the we the of as the by and that neutrophil (3 in that of neutrophils the in the by the neutrophil neutrophil of by the of neutrophils the of neutrophils that of and an in the early after initiating high-fat feeding in that of neutrophils and the of neutrophils and the of neutrophils of of neutrophils by of by as in in the of are of of neutrophils and and the neutrophils and of neutrophils of of in the neutrophils in the in the of of neutrophils in the of the and neutrophils are the in neutrophil is by of by and we neutrophil in and of of in the of of by and and the of of neutrophils and in in the of the of that in the of the that the is the of neutrophil in the we of neutrophils the in the and the of neutrophils the of and the of neutrophils in neutrophils by and neutrophils the are of neutrophils in neutrophil by the neutrophil we the of and the an of the of by neutrophils the in the and in the of demonstrate that and are of the of the and are of by and by of neutrophils in the of the of are of in in is of the of is we the of the that is of in and in inflammation and We the the of neutrophils in and in the by neutrophils we demonstrate an and the and of by of and of the that of neutrophils the of the of in the and of the in of and in of neutrophils we that of the of by the the that the neutrophils and is by the and by neutrophils and neutrophil and expression of in in by of in are of neutrophils the are of neutrophils in of and and by and of by the of of are of obesity and the the adipose tissue of that fat is of the of obesity an in fat inflammation in fat in the of of of fat by of an of and the in intra-abdominal fat by of fat in of fat adipose tissue in obesity in the of fat the adipose tissue early in the of high-fat feeding of neutrophils transiently infiltrate the parenchyma of intra-abdominal adipose and in neutrophils in that is by and by the neutrophil but is of is by the of by neutrophil and that inflammatory is by inflammatory by neutrophils is in inflammation an the that adipose tissue in high-fat feeding the of adipose tissue inflammation in by the that the is in adipose tissue in obesity and of the in adipose tissue in obesity of inflammatory as of in adipose tissue. of in adipose in and and in fat and as as an as and inflammatory of and and the of the adipose tissue as an infiltration of into adipose tissue is macrophage in adipose and and in by inflammatory and and inflammatory of and that adipose tissue inflammation may inflammation and the the inflammatory cascade is in obesity unknown. are the demonstrate that high-fat feeding of neutrophils intra-abdominal tissue. inflammatory as an early high-fat and inflammatory infiltration into adipose tissue of infiltrate adipose tissue adipose tissue and obesity macrophage and in adipose tissue of and neutrophils are in adipose infiltration the of initiating high-fat feeding and adipose tissue and obesity neutrophil infiltration into adipose tissue is is neutrophil neutrophils of infiltration and and by adipose tissue in obesity of in adipose tissue. of in adipose may as as and and of the adipose that neutrophil are in the of adipose tissue in and inflammation in adipose inflammation by and in adipose tissue infiltration of neutrophils may that in high-fat feeding neutrophils are the adipose tissue infiltrate the parenchyma and are in in an of neutrophils is by neutrophil and of neutrophil an the of in the the of of the of neutrophils and and the of by and the of by neutrophils and of inflammatory infiltration into adipose tissue the of obesity is by the in of adipose tissue in the of adipose tissue and obesity and macrophage infiltration inflammatory and of high-fat the of macrophage infiltration into intra-abdominal adipose tissue infiltration of in adipose tissue is in and of infiltration of in adipose tissue is in infiltration into fat of and the of still the and adipose tissue in in the in adipose tissue inflammation and of infiltration of into adipose in adipose tissue and of in adipose and but adipose tissue inflammation is the of neutrophils are in that neutrophils in adipose tissue and of the and is of that of and into is the of an inflammatory but the of inflammatory as and in of neutrophils in the and of of and in the of the inflammatory cascade in inflammatory in of neutrophils in the and of of the of adipose tissue inflammation as neutrophil infiltration in initiating the inflammatory cascade in high-fat is as by inflammation inflammatory in adipose is by of inflammatory and and by an of of in adipose tissue. of in adipose and in and and in fat the tissue in in as an and as of inflammatory of the of adipose tissue in the are of as and and adipose tissue in obesity by of are of is macrophage in adipose inflammation in fat in the of now that infiltration of immune in the of that infiltration into adipose tissue in mice, and the of inflammatory and of high-fat macrophage infiltration into adipose and in the of macrophage infiltration into the fat in the and of infiltration of in adipose tissue is in infiltration into fat of and the of the in in and the of inflammatory and inflammatory of and adipose tissue may by immune and may the of obesity of adipose tissue infiltration by in the high-fat of macrophage infiltration of obesity is macrophage in adipose adipose tissue and obesity and inflammatory inflammatory infiltration of by infiltrate is by infiltration of the tissue by neutrophils and may the that in an established of adipose tissue may by immune of the and the that adipose tissue that neutrophils we hypothesized that neutrophil infiltration of adipose tissue may precede the macrophage we the that neutrophils transiently infiltrate adipose tissue as early as after initiating high-fat in We in that neutrophil and and and in the of neutrophils myeloperoxidase and and by and and the the of the and of C57BL/6J of high-fat as adipose tissue and obesity and and by and periepdidymal and fat in the and in and in an of 7 tissue and and into in as we of and in and the of by of by and of in of and by and by after of and of of and and the in neutrophils of and in neutrophils the and the the in of and in the by of the the in the as the of by neutrophils as the of by the as of of the of neutrophils the and in and as of by of of and as the expression of in neutrophils in in the the and by expression of in and the the and by and fat in and of and the the and adipose fat neutrophils by and of in and the the and the neutrophils in in and the of the and as of and in and in the of the as of the of in of and in of in the neutrophils and the in of the and and in of the of and the in in and the of the and the and by neutrophils as of in the of and by and into and the by the in in and of by in of the and fat in and by in of macrophage and in adipose tissue of and and in of in and of by in of by the the and in an of macrophage by the of are as of by of the and and in the of neutrophils myeloperoxidase and and in the of neutrophils myeloperoxidase and and by and and the the of the and of C57BL/6J of high-fat as adipose tissue and obesity and and by and periepdidymal and fat in the and in and in an of 7 tissue by and and the the of the and of C57BL/6J of high-fat as adipose tissue and obesity and and by and periepdidymal and fat in the and in and in an of 7 tissue and and into in as we of and in and the of by and into in as we of and in and the of by of by and of in of and by and by after of and of by and of in of and by and by after of and of of and and the in neutrophils of and in neutrophils the and the the in of and in the by of the the in the as the of of and and the in neutrophils of and in neutrophils the and the the in of and in the by of the the in the as the of by neutrophils as the of by the as of of the of neutrophils the and in and as of by of of and as the of by neutrophils as the of by the as of of the of neutrophils the and in and as of by of of and as the expression of in neutrophils in in the the and by neutrophils in in the the and by expression of in and the the and by and the the and by and fat in and of and the the and adipose fat neutrophils by and of in and the the and the neutrophils in in and the of the and as of and in and in the of the as of the of in of and in and fat in and of and the the and adipose fat neutrophils by and of in and the the and the neutrophils in in and the of the and as of and in and in the of the as of the of in of and in of in the neutrophils and the in of the and and in of the of and the in in and the of the and the the neutrophils and the in of the and and in of the of and the in in and the of the and the and by neutrophils as of in the of and by and into and the by the in in and of by in of the and fat in and by in of macrophage and in adipose tissue of and and in of in and of by in of by the the and in an of macrophage by the of by neutrophils as of in the of and by and into and the by the in in and of by in of the and fat in and by in of macrophage and in adipose tissue of and and in of in and of by in of by the the and in an of macrophage by the of are as of by of the are as of by of the neutrophils infiltrate adipose tissue macrophage we C57BL/6J mice, obesity high-fat high-fat an of in as early as after of high-fat feeding and high-fat mice, in of in adipose tissue the of adipose tissue we of adipose tissue the the neutrophil adipose tissue expression and and and and of adipose tissue expression of in is in Mean periepdidymal fat expression and and 7 and in expression in in expression in adipose tissue and high-fat and and neutrophils that that of adipose tissue the the of neutrophils the parenchyma of the adipose tissue in neutrophils by in adipose tissue neutrophils in fat of high-fat and 7 high-fat but established adipose tissue by as by macrophage and in adipose tissue of and and 7 and and the of expression that of in intra-abdominal fat of tissue demonstrate that neutrophils transiently infiltrate intra-abdominal adipose tissue early in the of by the infiltration of adipose tissue by the of we an in the of neutrophils the We the in neutrophils the of the in We by neutrophils of of the neutrophils the and of by the of neutrophils the the in the of neutrophils and in the of of the of in the we the of as the by and that neutrophil (3 in that of neutrophils the in the by the neutrophil neutrophil of by the of neutrophils the of neutrophils that of and an in the early after initiating high-fat feeding in that of neutrophils and the of neutrophils and the of neutrophils of of neutrophils by of by as in in the of are of of neutrophils and and the neutrophils and of neutrophils of of in the neutrophils in the in the of of neutrophils in the of the and neutrophils are the in neutrophil is by of by and we neutrophil in and of of in the of of by and and the of of neutrophils and in in the of the of that in the of the that the is the of neutrophil in the we of neutrophils the in the and the of neutrophils the of and the of neutrophils in neutrophils by and neutrophils the are of neutrophils in neutrophil by the neutrophil we the of and the an of the of by neutrophils the in the and in the of demonstrate that and are of the of the and are of by and by of neutrophils in the of the of are of in in is of the of is we the of the that is of in and in inflammation and We the the of neutrophils in and in the by neutrophils we demonstrate an and the and of by of and of the that of neutrophils the of the of in the and of the in of and in of neutrophils we that of the of by the the that the neutrophils and is by the and by neutrophils and neutrophil and expression of in in by of in are of neutrophils the are of neutrophils in of and and by and of by the of of are of neutrophils infiltrate adipose tissue macrophage we C57BL/6J mice, obesity high-fat high-fat an of in as early as after of high-fat feeding and high-fat mice, in of in adipose tissue the of adipose tissue we of adipose tissue the the neutrophil adipose tissue expression and and and and of adipose tissue expression of in is in Mean periepdidymal fat expression and and 7 and in expression in in expression in adipose tissue and high-fat and and neutrophils that that of adipose tissue the the of neutrophils the parenchyma of the adipose tissue in neutrophils by in adipose tissue neutrophils in fat of high-fat and 7 high-fat but established adipose tissue by as by macrophage and in adipose tissue of and and 7 and and the of expression that of in intra-abdominal fat of tissue demonstrate that neutrophils transiently infiltrate intra-abdominal adipose tissue early in the of by the infiltration of adipose tissue by the of we an in the of neutrophils the We the in neutrophils the of the in We by neutrophils of of the neutrophils the and of by the of neutrophils the the in the of neutrophils and in the of of the of in the we the of as the by and that neutrophil (3 in that of neutrophils the in the by the neutrophil neutrophil of by the of neutrophils the of neutrophils that of and an in the early after initiating high-fat feeding in that of neutrophils and the neutrophils in the in the of of neutrophils in the of the and neutrophils are the neutrophil is by of by and we neutrophil in and of of in the of of by and and the of of neutrophils and in in the of the of that in the of the that the is the of neutrophil in the we of neutrophils the in the and the neutrophil by the neutrophil we the of and the an of the of by neutrophils the in the and in the of demonstrate that and are of the of the is we the of the that is of in and in inflammation and We the the of neutrophils in and in the by neutrophils we demonstrate an and the and of by of and of the that of neutrophils the of the of in the and of the in of and in of neutrophils we that of the of by the the that the neutrophils and is by the and by neutrophils and obesity and the the adipose tissue of that fat is of the of obesity an in fat inflammation in fat in the of of of fat by of an of and the in intra-abdominal fat by of fat in of fat adipose tissue in obesity in the of fat the adipose tissue early in the of high-fat feeding of neutrophils transiently infiltrate the parenchyma of intra-abdominal adipose and in neutrophils in that is by and by the neutrophil but is of is by the of by neutrophil and that inflammatory is by inflammatory by neutrophils is in inflammation an the that adipose tissue in high-fat feeding the of adipose tissue inflammation in by the that the is in adipose tissue in obesity and of the in adipose tissue in obesity of inflammatory as of in adipose tissue. of in adipose in and and in fat and as as an as and inflammatory of and and the of the adipose tissue as an infiltration of into adipose tissue is macrophage in adipose and and in by inflammatory and and inflammatory of and that adipose tissue inflammation may inflammation and the the inflammatory cascade is in obesity unknown. are the demonstrate that high-fat feeding of neutrophils intra-abdominal tissue. inflammatory as an early high-fat and inflammatory infiltration into adipose tissue of infiltrate adipose tissue adipose tissue and obesity macrophage and in adipose tissue of and neutrophils are in adipose infiltration the of initiating high-fat feeding and adipose tissue and obesity neutrophil infiltration into adipose tissue is is neutrophil neutrophils of infiltration and and by adipose tissue in obesity of in adipose tissue. of in adipose may as as and and of the adipose that neutrophil are in the of adipose tissue in and inflammation in adipose inflammation by and in adipose tissue infiltration of neutrophils may that in high-fat feeding neutrophils are the adipose tissue infiltrate the parenchyma and are in in an of neutrophils is by neutrophil and of neutrophil an the of in the the of of the of neutrophils and and the of by and the of by neutrophils and of inflammatory infiltration into adipose tissue the of obesity is by the in of adipose tissue in the of adipose tissue and obesity and macrophage infiltration inflammatory and of high-fat the of macrophage infiltration into intra-abdominal adipose tissue infiltration of in adipose tissue is in and of infiltration of in adipose tissue is in infiltration into fat of and the of still the and adipose tissue in in the in adipose tissue inflammation and of infiltration of into adipose in adipose tissue and of in adipose and but adipose tissue inflammation is the of neutrophils are in that neutrophils in adipose tissue and of the and is of that of and into is the of an inflammatory but the of inflammatory as and in of neutrophils in the and of of and in the of the inflammatory cascade in inflammatory in of neutrophils in the and of of the of adipose tissue inflammation as neutrophil infiltration in initiating the inflammatory cascade in high-fat obesity and the the adipose tissue of that fat is of the of obesity an in fat inflammation in fat in the of of of fat by of an of and the in intra-abdominal fat by of fat in of fat adipose tissue in obesity in the of fat the adipose tissue early in the of high-fat feeding of neutrophils transiently infiltrate the parenchyma of intra-abdominal adipose and in neutrophils in that is by and by the neutrophil but is of is by the of by neutrophil and that inflammatory is by inflammatory by neutrophils is in inflammation an the that adipose tissue in high-fat feeding the of adipose tissue inflammation in by the that the is in adipose tissue in obesity and of the in adipose tissue in obesity of inflammatory as of in adipose tissue. of in adipose in and and in fat and as as an as and inflammatory of and and the of the adipose tissue as an infiltration of into adipose tissue is macrophage in adipose and and in by inflammatory and and inflammatory of and that adipose tissue inflammation may inflammation and the the inflammatory cascade is in obesity unknown. are the demonstrate that high-fat feeding of neutrophils intra-abdominal tissue. inflammatory as an early high-fat and inflammatory infiltration into adipose tissue of infiltrate adipose tissue adipose tissue and obesity macrophage and in adipose tissue of and neutrophils are in adipose infiltration the of initiating high-fat feeding and adipose tissue and obesity neutrophil infiltration into adipose tissue is is neutrophil neutrophils of infiltration and and by adipose tissue in obesity of in adipose tissue. of in adipose may as as and and of the adipose that neutrophil are in the of adipose tissue in and inflammation in adipose inflammation by and in adipose tissue infiltration of neutrophils may that in high-fat feeding neutrophils are the adipose tissue infiltrate the parenchyma and are in in an of neutrophils is by neutrophil and of neutrophil an the of in the the of of the of neutrophils and and the of by and the of by neutrophils and of inflammatory infiltration into adipose tissue the of obesity is by the in of adipose tissue in the of adipose tissue and obesity and macrophage infiltration inflammatory and of high-fat the of macrophage infiltration into intra-abdominal adipose tissue infiltration of in adipose tissue is in and of infiltration of in adipose tissue is in infiltration into fat of and the of still the and adipose tissue in in the in adipose tissue inflammation and of infiltration of into adipose in adipose tissue and of in adipose and but adipose tissue inflammation is the of neutrophils are in that neutrophils in adipose tissue and of the and is of that of and into is the of an inflammatory but the of inflammatory as and in of neutrophils in the and of of and in the of the inflammatory cascade in inflammatory in of neutrophils in the and of of the of adipose tissue inflammation as neutrophil infiltration in initiating the inflammatory cascade in high-fat is by and and

a number of pathways, including interference with capacitation and possible damage to sperm membrane and DNA, which may impair the sperm's potential to fertilize an egg and develop into a healthy embryo. Adequate evaluation of male reproductive potential should therefore include an assessment of sperm OS. We propose the term Male Oxidative Stress Infertility, or MOSI, as a novel descriptor for infertile men with abnormal semen characteristics and OS, including many patients who were previously classified as having idiopathic male infertility. Oxidation-reduction potential (ORP) can be a useful clinical biomarker for the classification of MOSI, as it takes into account the levels of both oxidants and reductants (antioxidants). Current treatment protocols for OS, including the use of antioxidants, are not evidence-based and have the potential for complications and increased healthcare-related expenditures. Utilizing an easy, reproducible, and cost-effective test to measure ORP may provide a more targeted, reliable approach for administering antioxidant therapy while minimizing the risk of antioxidant overdose. With the increasing awareness and understanding of MOSI as a distinct male infertility diagnosis, future research endeavors can facilitate the development of evidence-based treatments that target its underlying cause.

Importance: Adjusting positive end-expiratory pressure (PEEP) to offset pleural pressure might attenuate lung injury and improve patient outcomes in acute respiratory distress syndrome (ARDS). Objective: To determine whether PEEP titration guided by esophageal pressure (PES), an estimate of pleural pressure, was more effective than empirical high PEEP-fraction of inspired oxygen (Fio2) in moderate to severe ARDS. Design, Setting, and Participants: Phase 2 randomized clinical trial conducted at 14 hospitals in North America. Two hundred mechanically ventilated patients aged 16 years and older with moderate to severe ARDS (Pao2:Fio2 ≤200 mm Hg) were enrolled between October 31, 2012, and September 14, 2017; long-term follow-up was completed July 30, 2018. Interventions: Participants were randomized to PES-guided PEEP (n = 102) or empirical high PEEP-Fio2 (n = 98). All participants received low tidal volumes. Main Outcomes and Measures: The primary outcome was a ranked composite score incorporating death and days free from mechanical ventilation among survivors through day 28. Prespecified secondary outcomes included 28-day mortality, days free from mechanical ventilation among survivors, and need for rescue therapy. Results: Two hundred patients were enrolled (mean [SD] age, 56 [16] years; 46% female) and completed 28-day follow-up. The primary composite end point was not significantly different between treatment groups (probability of more favorable outcome with PES-guided PEEP: 49.6% [95% CI, 41.7% to 57.5%]; P = .92). At 28 days, 33 of 102 patients (32.4%) assigned to PES-guided PEEP and 30 of 98 patients (30.6%) assigned to empirical PEEP-Fio2 died (risk difference, 1.7% [95% CI, -11.1% to 14.6%]; P = .88). Days free from mechanical ventilation among survivors was not significantly different (median [interquartile range]: 22 [15-24] vs 21 [16.5-24] days; median difference, 0 [95% CI, -1 to 2] days; P = .85). Patients assigned to PES-guided PEEP were significantly less likely to receive rescue therapy (4/102 [3.9%] vs 12/98 [12.2%]; risk difference, -8.3% [95% CI, -15.8% to -0.8%]; P = .04). None of the 7 other prespecified secondary clinical end points were significantly different. Adverse events included gross barotrauma, which occurred in 6 patients with PES-guided PEEP and 5 patients with empirical PEEP-Fio2. Conclusions and Relevance: Among patients with moderate to severe ARDS, PES-guided PEEP, compared with empirical high PEEP-Fio2, resulted in no significant difference in death and days free from mechanical ventilation. These findings do not support PES-guided PEEP titration in ARDS. Trial Registration: ClinicalTrials.gov Identifier NCT01681225.

The identification of mutations in genes that cause human diseases has largely been accomplished through the use of positional cloning, which relies on linkage mapping. In studies of rare diseases, the resolution of linkage mapping is limited by the number of available meioses and informative marker density. One recent advance is the development of high-density SNP microarrays for genotyping. The SNP arrays overcome low marker informativity by using a large number of markers to achieve greater coverage at finer resolution. We used SNP microarray genotyping for homozygosity mapping in a small consanguineous Israeli Bedouin family with autosomal recessive Bardet-Biedl syndrome (BBS; obesity, pigmentary retinopathy, polydactyly, hypogonadism, renal and cardiac abnormalities, and cognitive impairment) in which previous linkage studies using short tandem repeat polymorphisms failed to identify a disease locus. SNP genotyping revealed a homozygous candidate region. Mutation analysis in the region of homozygosity identified a conserved homozygous missense mutation in the TRIM32 gene, a gene coding for an E3 ubiquitin ligase. Functional analysis of this gene in zebrafish and expression correlation analyses among other BBS genes in an expression quantitative trait loci data set demonstrate that TRIM32 is a BBS gene. This study shows the value of high-density SNP genotyping for homozygosity mapping and the use of expression correlation data for evaluation of candidate genes and identifies the proteasome degradation pathway as a pathway involved in BBS.